Praxis will receive an upfront payment from UCB, and if the option is exercised by UCB, would be eligible to receive an option fee and future success-based development and commercialization milestone payments, for a total of up to ~$100M, in addition to tiered royalties on net sales of any resulting products from the collaboration.
Stock up 2.3% after-hours.